Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Express Scripts
Boehringer Ingelheim
Moodys
McKinsey

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Patent: 7,608,723

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 7,608,723
Title:Indole and benzimidazole derivatives
Abstract: The present invention relates to new indole and benzimidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: ##STR00001##
Inventor(s): Boyce; Rustum S. (Singapore, CN), Xia; Yi (Palo Alto, CA), Guo; Hongyan (Foster City, CA), Mendenhull; Kris G. (Concord, CA), Walter; Annette O. (Mill Valley, CA), Wang; Weibo (Moraga, CA)
Assignee: Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA)
Application Number:11/251,440
Patent Claims:see list of patent claims

Details for Patent 7,608,723

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) 2024-10-19 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) 2024-10-19 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) 2024-10-19 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) 2024-10-19 RX Orphan search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) 2024-10-19 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,608,723

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Dow
Express Scripts
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.